49
views
0
recommends
+1 Recommend
6 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Soon after the novel coronavirus, SARS-CoV-2 (2019-nCoV), was first identified in a cluster of patients with pneumonia (Li et al., 2020), in the Chinese city of Wuhan on 31 December 2019, rapid human to human transmission was anticipated (Hui et al., 2020). The fast pace of transmission is wreaking havoc and stirring media hype and public health concern (Ippolito et al., 2020) globally. When the World Health Organization (WHO) declared the disease, (now officially named COVID-19) a Public Health Emergency of International Concern (PHEIC) on 31st January 2020 (WHO, 2020a), the Director General Dr Tedros Ghebreyesus justified the decision by stating that WHOs greatest concern was the potential for the virus to spread to countries with weaker health systems. Repeated outbreaks of other preventable emerging and re-emerging infectious diseases with epidemic potential have taken their toll on the health systems of many African countries. The devastating 2014–2016 Ebola Virus Epidemic (WHO, 2020b) in West Africa, demonstrated how ill-prepared the affected countries were to rapidly identify the infection and halt transmission (WHO, 2020d, Largent, 2016, Hoffman and Silverberg, 2018, Omoleke et al., 2016). Similarly, the smoldering remnants of the 2018–19 Ebola Virus outbreak in the Democratic Republic of Congo, have demonstrated even for health services with considerable experience of dealing with a certain emerging pathogen, geography and sociopolitical instability, can hamper the response (Aruna et al., 2019). A recent analysis of the spatial and temporal distribution of infectious disease epidemics, disasters and other potential public health emergencies in the WHO Africa Region highlighted that 41 African countries (87% of the continent) had at least one epidemic, and 21 countries (45%) had at least one epidemic annually (Talisuna et al., 2020). The top five causes of epidemics were Cholera, Measles, Viral haemorrhagic diseases, malaria and meningitis. Seven countries which experienced over 10 events, all had limited International Health Regulations (IHR) capacities which are now being developed. Most sub-Saharan African countries are operating at maximum capacity with the huge existing workload in hospitals and clinics. The WHO’s Joint External Evaluation reports, conducted since 2016, suggest that the ability to respond to an International Health Regulation hazard, such as the importation of an infectious disease like COVID-19, requires almost universal improvement across sub-Saharan Africa (WHO, 2020c).Thus, it is essential for African countries to take the lead, become proactive and prepare surveillance systems for the rapid detection of any imported cases of COVID-19, to prevent rapid spread as seen in China. The question arises, ‘Is Africa prepared and equipped to deal with yet another outbreak of a highly infectious disease – COVID-19? The answer to the question is, it is better prepared than ever before. Substantial progress has been made since the 2014–16 Ebola outbreak (WHO, 2020d), with lessons learned from previous and ongoing outbreaks, followed by significant investments into surveillance and preparedness (WHO, 2020d, Largent, 2016, Hoffman and Silverberg, 2018, Omoleke et al., 2016). Africa is now better prepared than ever before. Thus, African countries have been on heightened alert to detect and isolated any imported cases of COVID-19. There has been rapid response to the COVID-19 epidemic from Africa’s public health systems, well before any cases of COVID-19 had been reported from Africa. This response has been made possible with the re-organization of the WHO including the creation of the World Health Emergencies Programme; the establishment of the Africa Centers for Disease Control and Prevention (Africa CDC, 2020) and creation and funding of consortia such as the ONE-HUMAN-ANIMAL-HEALTH Africa-Europe research, training and capacity development network (PANDORA-ID-NET)(Pandora-ID-NET, 2020) for tackling emerging and re-emerging infections with epidemic potential. This ONE-HEALTH network works effectively and equitably together across all Africa regions, fully engaging with national disease control authorities and public health institutes, in close liaison with the Nigeria CDC, Africa CDC and other African and global public health agencies. Importantly, this consortium has allowed strengthening of communication and establishment of trust and ‘unity of purpose’ between African governments, Africa CDC, Nigeria CDC (Nigeria CDC, 2020), local communities and the PANDORA-ID-NET consortium local African and European public health workers and scientists. An estimated 2 million Chinese nationals live and work in Africa, and there is increasing travel in the opposite direction, with people going to China for education, business and leisure. Prior to the travel restrictions imposed after the COVID-19 outbreak, there were an average of eight flights a day operated between China and African cities (Haider et al., 2020a, Haider et al., 2020b). There are ongoing efforts in Africa to prepare to deal with imported cases or subsequent local outbreaks of COVID-19, led by the Africa CDC, Nigeria CDC, African Union, PANDORA-ID-NET and other research and capacity development and training consortia. Many African countries have already introduced screening of arrivals for COVID-19 at airports, and at some seaports. ‘First public health emergency responders’ from African countries met in Senegal in early February 2020 to equip themselves with the latest advances on COVID-19 diagnostics (Corman et al., 2020), prevention and healthcare knowledge. Over 20 African nations are now able to test for COVID-19. Several African countries have identified isolation and quarantine centers and Nigeria, Kenya, Ethiopia, Ivory Coast, Ghana, Uganda and Botswana have rapidly dealt with suspected cases carrying out laboratory tests, and in some cases, placing them in quarantine while laboratory tests were performed. Nigeria was one of the first countries to recognize the risk and start planning the response for COVID-19. In a massive effort of national coordination, a multi-sectoral National Coronavirus Preparedness Group was established by Nigeria CDC on January 7, 2020, one week after China first reported the cases and three weeks before WHO declared the disease to be of international concern. The country has also established diagnostic capacity for COVID-19 in three laboratories within the country in one month. Nigeria CDC has established a national team that meets daily to assess the risk coronavirus poses to the nation and review its response to it. Uganda quarantined more than 100 people who arrived at Entebbe International Airport, some at hospitals in Entebbe and Kampala, and others were confined in their homes. Zambia has dedicated two medical facilities in the capital, Lusaka, to quarantine people suspected of having the disease. They include designating a new 800-bed capacity hospital in Lusaka, funded and built by China development aid to Zambia. Thermal body scanners have also been set up at all ports of entry to detect travelers showing symptoms of the virus. Kenya has introduced mandatory screening at all ports of entry, and established isolation facilities and a rapid response team to handle suspected cases. South Africa has set up national and provincial response teams, designated 300 health officials to ports of entry and begun screening all travelers from China. The Africa CDC has trained numerous participants from across Africa, including Egypt, on enhancing detection of COVID-19 at points-of-entry in collaboration with US-CDC, WHO, and the International Civil Aviation Authority (WHO, 2020e). Two airlines, Kenya Airways and South African Airlines, were also represented in the training. Additional training and resources have been provided to Egypt and other at-risk countries for infection prevention and control in healthcare facilities, medical management of COVID-19, and risk communication and community engagement. The Africa Union, West African Health Organization (WAHO) and external donors have been quick to provide support to the Africa CDC. In response to emergency grant calls for COVID-19, there have been several consortia fielding grant applications for research and capacity development. The long anticipated and inevitable and detection of the introduction of SARS-CoV-2 into Africa was announced on 14 February 2020, by the Minister of Health and Population of Egypt, Dr Hala Zayed, who confirmed the first case of the novel coronavirus disease COVID-19 in Egypt. The patient was a 33 year old male of foreign origin whose 17 contacts tested negative but were under home quarantine for 14 days. This has ignited a reflection on the readiness of the continent to take on the challenge and showcase its new potential. Following detection of this first case in Africa, the Africa CDC, Nigeria CDC and other national public health institutes in liaison with the WHO are scaling up preparedness efforts in the African region, supporting countries to implement recommendations outlined by the WHO International Health Regulations Emergency Committee. The Emergency Committee recommended that all countries should be prepared for containment, including active surveillance, early detection, isolation and case management, contact tracing and prevention of onward spread of SARS-CoV-2. Thirteen nations with close links with China, including Nigeria, South Africa, Kenya and the Democratic Republic of the Congo, have been identified as especially high-risk priority zones for proactive surveillance, detection and containing the spread of COVID-19. The WHO has sent diagnostic kits to 29 laboratories in Africa, and reagents and positive controls are being shipped worldwide by PANDORA-ID-NET partner in Germany, Charité-Universitätsmedizin Berlin Institute of Virology, to ensure the capacity to screen and test. Some countries in Africa, including DRC, are also leveraging the capacity they have built up to test for Ebola, to test for COVID-19. Thus, early detection of cases with implementation of infection control procedures will remain a priority to control the spread of COVID-19 in Africa. On 22nd February, 2020 an Emergency Ministerial meeting on COVID-19 was organized by the African Union and the Africa Centres for Disease Control and Prevention following which the WHO DG announced several additional measures and plans for supporting the Africa response to COVID-19 (WHO, 2020g). He appointed Dr John Nkengasong, Director of the Africa CDC, and Professor Samba Sow, Director-General of the Center for Vaccine Development in Mali, as special envoys on COVID-19, to provide strategic advice and high-level political advocacy and engagement in Africa. A WHO Strategic Preparedness and Response Plan has been developed, with a call for US$675 million to support those African countries which are most vulnerable. WHO have also shipped over 30,000 sets of personal protective equipment to several countries in Africa, and 60,000 more sets are to be shipped to the 19 vulnerable countries in the coming weeks. During the past month about 11,000 African health workers have been trained using WHO’s online courses on COVID-19, which are available free of charge in English, French and other languages at OpenWHO.org. As of 5th March, 2020, worldwide there were 93,090 laboratory confirmed cases of COVID-19 reported to the WHO. Of these 80,422 cases (with 2,984 deaths) were from China, and 12,668 cases (with 214 deaths) were from 76 countries outside China. From Africa there have been 5 cases from Algeria, 1 from Nigeria, 1 from Senegal and 2 from Egypt (WHO, 2020f). Given the extent of the outbreak in China, and with a high degree of awareness of COVID-19 in Africa, and proactive screening on the rise, more COVID-19 cases are anticipated in Africa. Several lessons have been learnt from the SARS-CoV-2 epidemic, which is the third lethal human zoonotic coronavirus with epidemic potential to emerge past 2 decades, the first being SARS-CoV identified in 2002 and second MERS-CoV in 2012 (Hui et al., 2014, McCloskey et al., 2014). Whilst the news and social media hype has evoked public and political anxieties, it is important to note that COVID-19 appears to have less than 3% mortality rates and is not more serious than outbreaks of viral respiratory tract infections such as influenza (Ippolito et al., 2020). It is crucial that other communicable diseases which impact a higher toll and burden on health services in Africa are not neglected or sidelined by the current hype and scaremongering of the COVID-19 epidemic. An important need remains for ensuring long-term sustainability of what is being built. Africa needs to continue its upward trajectory of activities so as to align public health resources, scientific expertise and experience, and political commitment so that any future infectious disease outbreaks can be stopped before they become an epidemic in Africa. Africa needs more investments into ONE-HEALTH collaborative activities across the continent in order to meet the challenges of current and future public health threats (Kock et al., 2020, Petersen et al., 2019, Talisuna et al., 2020, Hui et al., 2020, Zumla et al., 2016). A whole new young generation of enthusiastic, committed and dedicated African public health workers, epidemiologists, researchers, healthcare workers and laboratory personnel have emerged over the past 5 years, and they need to be supported by security of funding to build their careers and sustain their capabilities to take forward their research and training portfolios. The future of Africa’s public health security relies on them. Increased governmental and donor investments are required to advance locally led, world-class public health work with surveillance, data and analytics capabilities and further expanding state-of-the-art laboratory capacities with more trained personnel to sustain capacity to rapidly respond to outbreaks at their source. A well-planned long-term strategy from the Africa Union will add major value for consolidating African leadership of public health capacity building, training and research. Conflicts of interest All author declare no other conflicts of interest Author contributions Sir Prof Alimuddin Zumla, Dr Nathan Kapata, Dr Chikwe Ihekweazu, Prof Giuseppe Ippolito and Prof Francine Ntoumi conceptualized the editorial and developed the first draft. All authors contributed to writing and finalizing the manuscript.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

          Abstract Background The initial cases of novel coronavirus (2019-nCoV)–infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the first 425 confirmed cases in Wuhan to determine the epidemiologic characteristics of NCIP. Methods We collected information on demographic characteristics, exposure history, and illness timelines of laboratory-confirmed cases of NCIP that had been reported by January 22, 2020. We described characteristics of the cases and estimated the key epidemiologic time-delay distributions. In the early period of exponential growth, we estimated the epidemic doubling time and the basic reproductive number. Results Among the first 425 patients with confirmed NCIP, the median age was 59 years and 56% were male. The majority of cases (55%) with onset before January 1, 2020, were linked to the Huanan Seafood Wholesale Market, as compared with 8.6% of the subsequent cases. The mean incubation period was 5.2 days (95% confidence interval [CI], 4.1 to 7.0), with the 95th percentile of the distribution at 12.5 days. In its early stages, the epidemic doubled in size every 7.4 days. With a mean serial interval of 7.5 days (95% CI, 5.3 to 19), the basic reproductive number was estimated to be 2.2 (95% CI, 1.4 to 3.9). Conclusions On the basis of this information, there is evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019. Considerable efforts to reduce transmission will be required to control outbreaks if similar dynamics apply elsewhere. Measures to prevent or reduce transmission should be implemented in populations at risk. (Funded by the Ministry of Science and Technology of China and others.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

            Background The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. Aim We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. Methods Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. Results The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive – Global (EVAg), a European Union infrastructure project. Conclusion The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

              The city of Wuhan in China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a coronavirus 2019-nCoV. In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei province in China, with an epidemiological link to the Huanan Seafood Wholesale Market where there was also sale of live animals. Notification of the WHO on 31 Dec 2019 by the Chinese Health Authorities has prompted health authorities in Hong Kong, Macau, and Taiwan to step up border surveillance, and generated concern and fears that it could mark the emergence of a novel and serious threat to public health (WHO, 2020a, Parr, 2020). The Chinese health authorities have taken prompt public health measures including intensive surveillance, epidemiological investigations, and closure of the market on 1 Jan 2020. SARS-CoV, MERS-CoV, avian influenza, influenza and other common respiratory viruses were ruled out. The Chinese scientists were able to isolate a 2019-nCoV from a patient within a short time on 7 Jan 2020 and perform genome sequencing of the 2019-nCoV. The genetic sequence of the 2019-nCoV has become available to the WHO on 12 Jan 2020 and this has facilitated the laboratories in different countries to produce specific diagnostic PCR tests for detecting the novel infection (WHO, 2020b). The 2019-nCoV is a β CoV of group 2B with at least 70% similarity in genetic sequence to SARS-CoV and has been named 2019-nCoV by the WHO. SARS is a zoonosis caused by SARS-CoV, which first emerged in China in 2002 before spreading to 29 countries/regions in 2003 through a travel-related global outbreak with 8,098 cases with a case fatality rate of 9.6%. Nosocomial transmission of SARS-CoV was common while the primary reservoir was putatively bats, although unproven as the actual source and the intermediary source was civet cats in the wet markets in Guangdong (Hui and Zumla, 2019). MERS is a novel lethal zoonotic disease of humans endemic to the Middle East, caused by MERS-CoV. Humans are thought to acquire MERS-CoV infection though contact with camels or camel products with a case fatality rate close to 35% while nosocomial transmission is also a hallmark (Azhar et al., 2019). The recent outbreak of clusters of viral pneumonia due to a 2019-nCoV in the Wuhan market poses significant threats to international health and may be related to sale of bush meat derived from wild or captive sources at the seafood market. As of 10 Jan 2020, 41 patients have been diagnosed to have infection by the 2019-nCoV animals. The onset of illness of the 41 cases ranges from 8 December 2019 to 2 January 2020. Symptoms include fever (>90% cases), malaise, dry cough (80%), shortness of breath (20%) and respiratory distress (15%). The vital signs were stable in most of the cases while leucopenia and lymphopenia were common. Among the 41 cases, six patients have been discharged, seven patients are in critical care and one died, while the remaining patients are in stable condition. The fatal case involved a 61 year-old man with an abdominal tumour and cirrhosis who was admitted to a hospital due to respiratory failure and severe pneumonia. The diagnoses included severe pneumonia, acute respiratory distress syndrome, septic shock and multi-organ failure. The 2019-nCoV infection in Wuhan appears clinically milder than SARS or MERS overall in terms of severity, case fatality rate and transmissibility, which increases the risk of cases remaining undetected. There is currently no clear evidence of human to human transmission. At present, 739 close contacts including 419 healthcare workers are being quarantined and monitored for any development of symptoms (WHO, 2020b, Center for Health Protection and HKSAR, 2020). No new cases have been detected in Wuhan since 3 January 2020. However the first case outside China was reported on 13th January 2020 in a Chinese tourist in Thailand with no epidemiological linkage to the Huanan Seafood Wholesale Market. The Chinese Health Authorities have carried out very appropriate and prompt response measures including active case finding, and retrospective investigations of the current cluster of patients which have been completed; The Huanan Seafood Wholesale Market has been temporarily closed to carry out investigation, environmental sanitation and disinfection; Public risk communication activities have been carried out to improve public awareness and adoption of self-protection measures. Technical guidance on novel coronavirus has been developed and will continue to be updated as additional information becomes available. However, many questions about the new coronavirus remain. While it appears to be transmitted to humans via animals, the specific animals and other reservoirs need to be identified, the transmission route, the incubation period and characteristics of the susceptible population and survival rates. At present, there is however very limited clinical information of the 2019-nCoV infection and data are missing in regard to the age range, animal source of the virus, incubation period, epidemic curve, viral kinetics, transmission route, pathogenesis, autopsy findings and any treatment response to antivirals among the severe cases. Once there is any clue to the source of animals being responsible for this outbreak, global public health authorities should examine the trading route and source of movement of animals or products taken from the wild or captive conditions from other parts to Wuhan and consider appropriate trading restrictions or other control measures to limit. The rapid identification and containment of a novel coronavirus virus in a short period of time is a re-assuring and a commendable achievement by China’s public health authorities and reflects the increasing global capacity to detect, identify, define and contain new outbreaks. The latest analysis show that the Wuhan CoV cluster with the SARS CoV.10 (Novel coronavirus - China (01): (HU) WHO, phylogenetic tree Archive Number: 20200112.6885385). This outbreak brings back memories of the novel coronavirus outbreak in China, the severe acute respiratory syndrome (SARS) in China in 2003, caused by a novel SARS-CoV-coronavirus (World Health Organization, 2019a). SARS-CoV rapidly spread from southern China in 2003 and infected more than 3000 people, killing 774 by 2004, and then disappeared – never to be seen again. However, The Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) (World Health Organization, 2019b), a lethal zoonotic pathogen that was first identified in humans in the Kingdom of Saudi Arabia (KSA) in 2012 continues to emerge and re-emerge through intermittent sporadic cases, community clusters and nosocomial outbreaks. Between 2012 and December 2019, a total of 2465 laboratory-confirmed cases of MERS-CoV infection, including 850 deaths (34.4% mortality) were reported from 27 countries to WHO, the majority of which were reported by KSA (2073 cases, 772 deaths. Whilst several important aspects of MERS-CoV epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, have been defined, there remain many unanswered questions, including source, transmission and epidemic potential. The Wuhan outbreak is a stark reminder of the continuing threat of zoonotic diseases to global health security. More significant and better targeted investments are required for a more concerted and collaborative global effort, learning from experiences from all geographical regions, through a ‘ONE-HUMAN-ENIVRONMENTAL-ANIMAL-HEALTH’ global consortium to reduce the global threat of zoonotic diseases (Zumla et al., 2016). Sharing experience and learning from all geographical regions and across disciplines will be key to sustaining and further developing the progress being made. Author declarations All authors have a specialist interest in emerging and re-emerging pathogens. FN, RK, OD, GI, TDMc, CD and AZ are members of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020 Framework Programme for Research and Innovation. AZ is a National Institutes of Health Research senior investigator. All authors declare no conflicts of interest.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Infect Dis
                Int. J. Infect. Dis
                International Journal of Infectious Diseases
                The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
                1201-9712
                1878-3511
                28 February 2020
                April 2020
                28 February 2020
                : 93
                : 233-236
                Affiliations
                [0005]Zambia National Public Health Institute, Minsitry of Health, Lusaka, Zambia
                [0010]Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria
                [a ]University Marien NGouabi, Brazzaville, Congo
                [b ]Institute for Tropical Medicine/University of Tübingen, Germany
                [0025]Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia
                [0030]Ministry of Health, Lusaka, Zambia
                [0035]Lusaka Apex Medical University, Lusaka, Zambia
                [0040]National Public Health Institute, Ministry of Health, Lusaka, Zambia
                [0045]School of Life Sciences, University of Lincoln, Lincoln, United Kingdom
                [0050]HerpeZ and UNZA-UCLMS Project, University Teaching Hospital, Lusaka, Zambia
                [a ]Charité – Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany
                [b ]German Centre for Infection Research (DZIF), Berlin, Germany
                [0065]National Institute of Medical Research, Dar es Salaam, Tanzania
                [0070]Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria
                [0075]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom
                [0080]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom
                [0085]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom
                [0090]SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, Tanzania
                [0095]Institute of Health Informatics, Faculty of Pop Health Sciences, UCL, London, United Kingdom
                [0100]The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom
                [0105]The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom
                [0110]Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom
                [0115]Institute for Global Health, University College London, London, United Kingdom
                [0120]Faculty of Pharmacy, Montpellier University, IRD UMR5569, Montpellier, France
                [0125]Dept of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of Khartoum, Sudan
                [0130]Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, United Kingdom
                [0135]Ethics and Governance, University College London, London, United Kingdom
                [0140]National Institute for Infectious Diseases Lazzaro Spallanzani – IRCCS, Rome, Italy
                [0145]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom
                [a ]Charité – Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany
                [b ]German Centre for Infection Research (DZIF), Berlin, Germany
                [0160]The Royal Veterinary College, University of London, Hatfield, Hertfordshire, United Kingdom
                [0165]National Institute for Infectious Diseases – Lazzaro Spallanzani – IRCCS, Rome, Italy
                [a ]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, United Kingdom
                [b ]Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom
                Author notes
                [* ]Corresponding author. nkapata@ 123456gmail.com
                Article
                S1201-9712(20)30107-7
                10.1016/j.ijid.2020.02.049
                7129026
                32119980
                748e6e7a-d37c-4665-8033-ae067d134e57
                © 2020 The Author(s)

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 19 February 2020
                Categories
                Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article